Susan Lee, MD
Internal Medicine · Chatham, NJNPI 1669695623
Payments from drug & device makers
Across 88 payments — averaging $386.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$31K
- Amgen$560
- AbbVie$536
- UCB, Inc.$425
- GSK$221
- Lilly USA, LLC$137
- plus $634 from 15 others
Across 1 payment — averaging $768.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$769
What the payments were for
- Consulting fees$1606%
- Food & beverage$2,31492%
- Education$392%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 4 | $31,480 |
| Amgen(2 entities) | 17 | $560 |
| AbbVie | 11 | $536 |
| UCB, Inc. | 11 | $425 |
| GSK | 6 | $221 |
| Lilly USA, LLC | 8 | $137 |
| Johnson & Johnson | 3 | $79 |
| AstraZeneca | 5 | $78 |
| Novartis | 4 | $77 |
| Kedrion Biopharma, Inc. | 2 | $70 |
| Aurinia Pharma U.S., Inc. | 3 | $57 |
| Sandoz | 2 | $46 |
| Lundbeck LLC | 2 | $38 |
| ANI Pharmaceuticals, Inc. | 1 | $31 |
| Boehringer Ingelheim | 2 | $31 |
| Collegium Pharmaceutical, Inc. | 2 | $29 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$33,994 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 47 | $433,378 |
| Enbrel SureclickEtanercept | 23 | $181,109 |
| Cosentyx Sensoready PenSecukinumab | 19 | $147,514 |
| Hydroxychloroquine Sulfate | 429 | $18,992 |
| MethotrexateMethotrexate Sodium | 463 | $10,338 |
| Leflunomide | 77 | $6,212 |
| Sulfasalazine | 103 | $2,907 |
| Gabapentin | 155 | $2,353 |
| Duloxetine Hcl | 118 | $2,139 |
| Prednisone | 278 | $1,746 |
| Tramadol Hcl | 167 | $1,515 |
| Pregabalin | 75 | $1,434 |
| Colchicine | 16 | $1,004 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 37 | $850 |
| Celecoxib | 37 | $820 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Chatham
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.